Why the study?
Does dextran sulfate improve atherosclerosis through a modified fibrotic process in human aortas?
Case-Control (n=26)
No
Does dextran sulfate improve atherosclerosis through a modified fibrotic process in human aortas?
Answers are grounded in this paper and cite their sources.
Dextran sulfate may stabilize atherosclerotic plaques by promoting fibrous capsulation and reducing ulceration, suggesting that modifying the fibrotic process could be a therapeutic strategy against atherosclerosis.
Three hundred and eighty-nine autopsied human aortas were studied for lipid and fibrosis areas in the 6 segments which were expected to receive different grade and nature of hemodynamic stress.The fibrosis area was increasing with age as well as the lipid area. The grade of fibrosis was especially prominent at the location where hemodynamic stress was estimated to increase and in higher age female. Acid mucopolysaccharides (aMPS) content in the aortic wall was increased with age up to middle age and took a down hill course thereafter. The aMPS-age curve was identified as a differential of the fibrosisage curve. The relationship between aMPS and fibrosis was more intimate than that between aMPS and lipidosis. Histochemical study revealed proliferating fine collagen fibers in the location where aMPS was accumulated. It seemed true that the decreace of aMPS after middle age provoked progression of atheromatous change and made slow fibrotic process.Thirteen autopsied human aortas of the cases with long term peroral administration of dextran sulfate (D. S.), were studied with age-, sex-, blood pressure-, and atherosclerosis-matched controls. The D. S. group showed macroscopically same grade of atheromatous lesions with bleeding, necrosis and calcification, but significantly less ulcerations over the atheromas. On histochemical examination, the D. S. group showed more prominent fibrous capsulation and MPS-accumulation around the atheromatous foci with more active cellular activity than the controls.The fibrosis seemed to be the second best procedure against atherosclerosis, for the primary prevetinon or complete healing is not yet established at the present stage.
No takes yet. Share an insight, caveat, or question.
Ryozo Okada (1973) conducted a case-control in Atherosclerosis (n=26). Dextran sulfate vs. Matched controls was evaluated on Ulcerations over the atheromas.
Synapse has enriched 10 related papers. Consider them for comparative context: